Here's what I found:
The first two surveys provided the foundational data. A third survey, conducted in the fall of 2001, was done in response to many requests to further expand the list of exempt media. This collaborative, data-driven approach gave the standard significant weight in the clinical laboratory community when it was active in the U.S.
The document, titled Quality Control for Commercially Prepared Microbiological Culture Media , is a critical standard used by microbiology laboratories to ensure the reliability of their culture media while optimizing operational efficiency. Published by the Clinical and Laboratory Standards Institute (CLSI) , this third edition established the widely used "exempt" media list based on extensive performance data. Understanding the CLSI M22-A3 Standard
If you need a focused summary (e.g., QC ranges, step-by-step protocol, or differences from the prior edition), specify which section and I’ll generate a concise extract. clsi m22a3 pdf
Local or national regulations (like CLIA in the United States) may have stricter mandates that override certain CLSI exemptions.
Perform comprehensive QC testing on every batch/lot of media.
The primary premise of M22-A3 is to reduce the burden of redundant testing. It identifies specific media of "proven reliability" for which users do not need to perform additional retesting if the manufacturer's quality control (QC) practices meet established criteria. Here's what I found: The first two surveys
Chocolate Agar (susceptible to heating damage during prep), Campylobacter Agar, and selective media for fastidious organisms (e.g., Thayer-Martin Agar for Neisseria gonorrhoeae ). Manufacturer vs. User Responsibilities
Defining strict quality assurance metrics that commercial producers must meet before shipping products.
: Responsible for proper storage and transport to prevent damage (e.g., freezing or overheating). Users (Laboratories) Local or national regulations (like CLIA in the
Securing the official PDF documentation of CLSI M22-A3 is necessary for several operational and regulatory reasons:
: It operates on the premise that retesting is redundant for media that have historically demonstrated a failure rate of Clinical & Laboratory Standards Institute | CLSI Key Features of the Third Edition
Ensuring every batch matches its corresponding manufacturer certificate.
A critical takeaway from the M22-A3 document is the distinction between media that require user testing and those that do not. Exempt Media (Streamlined QC)
: The acceptable extrapolated failure rate for media to qualify as exempt was increased from 0.3% to 0.5% Defined Responsibilities